← Issue №19/ week of Nov 8, 2026/Colorectal

The genomic and epigenomic evolution of colorectal cancer.

From GI Signals issue №19: what this paper found, what it changes, and where it sits against the current standard of care, reviewed by Simon Mathews, MD.

Colorectal review · Nov 2, 2026 · Nat Rev Gastro Hep · IF 57.5

The genomic and epigenomic evolution of colorectal cancer.

Basic sciencebasic sciencetranslationalbiomarkercolorectal cancer
Clinical takeawayNo clinical action yet: a mechanistic review of genomic and epigenomic changes in colorectal cancer evolution.
What it foundThe review synthesizes genomic and epigenomic changes driving colorectal cancer evolution, from transformation to metastasis and treatment resistance.
ContextRefines understanding of colorectal cancer progression by integrating genetic, epigenetic, and immune changes, aligning with current knowledge of multistep carcinogenesis.
Measured against the standard of care· USMSTF 2020 (Shaukat et al.) / AGA Clinical Practice Update Commentary 2025 (Ngamruengphong et al.), created from: AGA Clinical Practice Update on Endoscopic Resection for Early Colorectal Cancer: Commentary (2025), https://doi.org/10.1053/j.gastro.2025.09.001

Decision at stakeunderstanding the molecular drivers of colorectal cancer evolution

For colorectal lesions suspected to contain early (T1) cancer, US practice follows the USMSTF 2020 guideline on malignant colorectal polyps, with the AGA 2025 Clinical Practice Update commentary added on top. …

From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text.

Our full summary of this standard

For colorectal lesions suspected to contain early (T1) cancer, US practice follows the USMSTF 2020 guideline on malignant colorectal polyps, with the AGA 2025 Clinical Practice Update commentary added on top. Management starts with a careful endoscopic assessment for features of deep submucosal invasion (for example, NICE type 3 or excavated morphology). A nonpedunculated lesion with deep-invasion features should be biopsied and tattooed, then referred for surgical resection. The AGA 2025 commentary adds that endoscopic local excision, including endoscopic full-thickness resection for selected T1 lesions under 2 cm, can be considered where technically feasible. A nonpedunculated lesion at high risk of superficial submucosal invasion should be removed en bloc, with proper specimen handling. ESD is often preferred to EMR because it achieves higher en bloc rates. Piecemeal resection of a suspected cancer is discouraged: it compromises histologic staging and independently predicts recurrence, and NCCN treats a T1 cancer removed piecemeal as needing surgery. After complete endoscopic removal of a malignant polyp, whether to recommend surgery depends on polyp shape, whether en bloc resection and an adequate histologic assessment were achieved, unfavorable histologic features (lymph node metastasis risk), surgical risk, and patient preference. The AGA 2025 commentary advises referral to a high-volume center with endoscopic resection and pathology expertise when the diagnosis is unclear and suspicion for cancer is high. It also advises expert GI pathology review and multidisciplinary discussion of resected T1 specimens. Lesions resected en bloc with no unfavorable histology can be managed with endoscopic surveillance instead of surgery.

USMSTF 2020 (Shaukat et al.) / AGA Clinical Practice Update Commentary 2025 (Ngamruengphong et al.), created from: AGA Clinical Practice Update on Endoscopic Resection for Early Colorectal Cancer: Commentary (2025), https://doi.org/10.1053/j.gastro.2025.09.001 · reviewed 2026-10-11 ↗
Sng CCT … Sottoriva A · Nature Reviews Gastroenterology & Hepatology · IF 57.5 · PubMed ↗Permalink
← Read the whole of issue №19 Every paper GI Signals surfaces gets a page like this one. All issues